重组人促红细胞生成素联合蔗糖铁治疗子宫肌瘤剔除术后中度贫血的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Objective To explore the effect of Recombinant Human Erythropoietin（rhEPO）combined with Iron Sucrose in the treatment of moderate anemia after myomectomy.Methods Fifty-nine patients with uterine fibroids complicated with moderate anemia treated in our hospital from May 2017 to May 2018 were selected as subjects.They were divided into study group（30 cases）and control group（29 cases）by the random number table method.Myomectomy was performed in both groups.The control group was treated with Iron Sucrose，and the study group was treated with rhEPO combined with Iron Sucrose.The clinical efficacy of the two groups was compared，and the hemoglobin（Hb）and mean erythrocyte volume（MCV）levels before operation and on the 5th and 14th day after operation were compared between the two groups.Results Levels of Hb（[92.15±11.30]，[103.47±12.17]g/L）and MCV（[75.23±10.13]，[79.05±10.14]fl）in the study group on the 5th and 14th day after operation were higher than those before operation（[79.1±10.03]g/L，[71.45±10.81]fl），the differences were statistically significant（P＜0.05）.Levels of Hb（[92.01±10.83]，[94.37±11.8]g/L）and MCV（[75.15±10.43]，[75.18±10.21]fl）in the control group on the 5th and 14th day after operation were higher than those before operation（[78.32±11.05]g/L，[71.41±10.96]fl），the differences were statistically significant（P＜0.05）.There were no significant differences in the Hb and MCV between the two groups before operation and on the 5th day after operation（P＞0.05）.The levels of Hb and MCV were higher in observation group than those in control group on the 14th day after operation，the differences were statistically significant（P＜0.05）.The total effective rate（93.33%）in the study group was higher than that in the control group（72.41%），and the difference was statistically significant（P＜0.05）.Conclusion Compared with Iron Sucrose alone，rhEPO combined with Iron Sucrose can relieve moderate anemia after myomectomy.Besides，the curative effects become better over time.

Key words： Recombinant Human Erythropoietin Iron Sucrose Uterine fibroids Moderate anemia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I4/143

[1]	常悦，钱景锋，高丽军，等.有生育要求的子宫肌瘤患者的治疗进展[J].实用妇产科杂志，2018，34（3）：186-189.
[2]	张浩，杨小妹，曹文芳，等.口服铁剂和静脉注射蔗糖铁对缺铁性贫血产妇治疗效果的Meta分析[J].临床和实验医学杂志，2017，16（12）：1178-1181.
[3]	潘军，胡江，许丽琴，等.蛋白琥珀酸铁联合输血治疗新生儿重度贫血安全性及疗效[J].临床军医杂志，2018，46（6）：707-709.
[4]	北京医学会输血医学分会，北京医师协会输血专业专家委员会.患者血液管理——术前贫血诊疗专家共识[J].中华医学杂志，2018，98（30）：2386-2392.
[5]	崔月清，王一娜.米非司酮在子宫肌瘤合并贫血术前预处理中的价值[J].中国妇幼保健，2017，32（17）：4087-4089.
[6]	彭敏，蔡鹏，李亚玲，等.输血护理安全敏感质量指标的构建与应用[J].护士进修杂志，2018，33（22）：2063-2065.
[7]	周烁，罗振中，徐国海，等.重组人促红细胞生成素用于围术期纠正贫血的研究进展[J].临床麻醉学杂志，2016，32（7）：709-712.
[8]	Petruliene K，ZiginskienE E，Kuzminskis V，et al.Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients[J].Medicina（Kaunas），2017，53（2）：90-100.
[9]	王云鹏，李晓东.不同剂量的重组人促红细胞生成素治疗早产儿贫血的效果分析[J].中国妇幼保健，2017，32（22）：5650-5652.
[10]	宋鑫，陈剑云，魏立强，等.重组人促红细胞生成素联合铁剂应用于消化道肿瘤相关性贫血的研究[J].中国医师杂志，2018，20（1）：114-116.
[11]	李璐兵，韩然，王雪，等.重组人红细胞生成素联合铁剂治疗在髋膝关节置换术贫血患者中的应用研究[J].实用骨科杂志，2016，22（10）：898-901.
[12]	Delzanno G，Falcone M，Gaudiano L，et al.Human recombinant erythropoietin in the treatment of anemia inobstetricgynecologic patients.Evaluation of such treatment as an alternative to blood transfusion[J].Minerva Ginecol，1996，48（3）：115-118.
[13]	Shepshelovich D，Rozen-Zvi B，Avni T，et al.Intravenous versus oral iron supplementation for the treatment of anemia in CKD：an updated systematic review and Meta-analysis[J].Am J Kidney Dis，2016，68（5）：677-690.
[14]	王树忠.蔗糖铁注射液治疗肾性贫血的疗效观察[J].医学临床研究，2015，32（9）：1736-1738.
[15]	徐金霞，吴兆晴，刘瑜.蔗糖铁静脉注射治疗晚期妊娠中度缺铁性贫血效果观察[J].山东医药，2017，57（34）：88-89.
[16]	杜林哲，朱余兵，刘赟心，等.重组人促红细胞生成素联合铁剂治疗围手术期贫血[J].药学与临床研究，2017，25（6）：537-539.